Mirae Asset Global Investments
CLDX icon

Mirae Asset Global Investments’s Celldex Therapeutics CLDX Stock Holding History

Mirae Asset Global Investments’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,779
Closed -$938K – 1719
2024
Q1 		$938K Sell
25,779
-479
-2% -$19.7K ﹤0.01% 1575
2023
Q4 		$1.04M Buy
26,258
+962
+4% +$28.3K ﹤0.01% 1598
2023
Q3 		$696K Sell
25,296
-1,730
-6% -$54.2K ﹤0.01% 1722
2023
Q2 		$922K Buy
27,026
+1,511
+6% +$50.9K ﹤0.01% 1617
2023
Q1 		$918K Buy
25,515
+5,986
+31% +$258K ﹤0.01% 1593
2022
Q4 		$870K Hold
19,529
– – ﹤0.01% 1572
2022
Q3 		$549K Buy
19,529
+5,780
+42% +$177K ﹤0.01% 1817
2022
Q2 		$371K Buy
+13,749
New +$399K ﹤0.01% 1888

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Mirae Asset Global Investments's CLDX Position: Q2 2024 in Review

Mirae Asset Global Investments sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 25,779 shares — an estimated $938K sold.

Mirae Asset Global Investments first reported a position in CLDX in Q2 2022 and held it in 8 quarters. The position peaked at $1.04M in Q4 2023. 183 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

  • Mirae Asset Global Investments reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 25,779 Celldex Therapeutics shares in Q2 2024, an estimated $938K.
  • Mirae Asset Global Investments first reported a position in Celldex Therapeutics in Q2 2022 and held it in 8 quarters.
  • Mirae Asset Global Investments's Celldex Therapeutics position peaked at $1.04M in Q4 2023.
  • 183 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on Mirae Asset Global Investments's 13F filing for Q2 2024, filed 30 Jul 2024.